Article Versions Notes

Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, et al. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers. 2022; 14(14):3473. https://doi.org/10.3390/cancers14143473

Hong, Lingzhi, Whitney E. Lewis, Monique Nilsson, Sonia Patel, Susan Varghese, Melvin J. Rivera, Robyn R. Du, Pingjun Chen, Haley N. Kemp, Waree Rinsurongkawong, and et al. 2022. "Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma" Cancers 14, no. 14: 3473. https://doi.org/10.3390/cancers14143473

Hong, L., Lewis, W. E., Nilsson, M., Patel, S., Varghese, S., Rivera, M. J., Du, R. R., Chen, P., Kemp, H. N., Rinsurongkawong, W., Heeke, S., Spelman, A. R., Elamin, Y. Y., Negrao, M. V., Sepesi, B., Gibbons, D. L., Lee, J. J., Wu, J., Vokes, N. I., ... Le, X. (2022). Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers, 14(14), 3473. https://doi.org/10.3390/cancers14143473